Celldex Therapeutics (CLDX +25%) goes on a tear today after reporting positive final results...

|About: Celldex Therapeutics, Inc (CLDX)|By:, SA News Editor

Celldex Therapeutics (CLDX +25%) goes on a tear today after reporting positive final results from Phase 2b studies of its breast cancer treatment CDX-011. Brean Capital was impressed, saying in a note to clients that the treatment "targets a clear and large unmet need," while Oppenheimer raised its price target from $6 to $8 and Jefferies from $7 to $9.